Arcutis Biotherapeutics, Inc.
Symbool: ARQT
NASDAQ
8.02
USDMarktprijs vandaag
-2.8364
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
926.51M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Arcutis Biotherapeutics, Inc. (ARQT) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1100.97 | 272.8 | 409.6 | 387.1 | |||||||
balance-sheet.row.short-term-investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.net-receivables | 75.2 | 25.8 | 8.5 | 0.4 | |||||||
balance-sheet.row.inventory | 46.07 | 13.1 | 7.5 | 1.2 | |||||||
balance-sheet.row.other-current-assets | 63.5 | 18.7 | 10.6 | 14.2 | |||||||
balance-sheet.row.total-current-assets | 1288.52 | 330.4 | 437.4 | 402.8 | |||||||
balance-sheet.row.property-plant-equipment-net | 17.21 | 3.9 | 4.6 | 5.3 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 1.87 | 0.6 | 0.1 | 0.1 | |||||||
balance-sheet.row.total-non-current-assets | 45.95 | 10.9 | 11.9 | 5.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.account-payables | 54.81 | 12 | 8.8 | 7.4 | |||||||
balance-sheet.row.short-term-debt | 2.82 | 0.7 | 0.7 | 0.4 | |||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.long-term-debt-total | 812.38 | 201.8 | 201.9 | 77.1 | |||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 104.61 | 33.9 | 28.3 | 25.5 | |||||||
balance-sheet.row.total-non-current-liabilities | 816.61 | 206 | 201.9 | 77.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 16.73 | 3.4 | 4.8 | 5.2 | |||||||
balance-sheet.row.total-liab | 978.85 | 252.7 | 239.7 | 110.5 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||
balance-sheet.row.retained-earnings | -3568.24 | -981.9 | -719.8 | -408.3 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.89 | 0 | -1.1 | -0.3 | |||||||
balance-sheet.row.other-total-stockholders-equity | 3924.73 | 1070.6 | 930.4 | 706.2 | |||||||
balance-sheet.row.total-stockholders-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 1334.47 | - | - | - | |||||||
Total Investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.total-debt | 818.58 | 205.9 | 202.5 | 77.6 | |||||||
balance-sheet.row.net-debt | 435.26 | 116.6 | 148.9 | -18.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -262.14 | -262.1 | -311.5 | -206.4 | |||||||
cash-flows.row.depreciation-and-amortization | 1.52 | 1.9 | 0.9 | 0.5 | |||||||
cash-flows.row.deferred-income-tax | -19.69 | 19.8 | 0 | 3.5 | |||||||
cash-flows.row.stock-based-compensation | 38.81 | 38.8 | 32.7 | 23.9 | |||||||
cash-flows.row.change-in-working-capital | -23.5 | -23.5 | -10.2 | 3.6 | |||||||
cash-flows.row.account-receivables | -17.35 | -17.3 | -8.5 | 0 | |||||||
cash-flows.row.inventory | -5.62 | -5.6 | -7.5 | 0 | |||||||
cash-flows.row.account-payables | 3.15 | 3.2 | 1.6 | 0.2 | |||||||
cash-flows.row.other-working-capital | -3.68 | -3.7 | 4.2 | 3.4 | |||||||
cash-flows.row.other-non-cash-items | 17.94 | -21.9 | 30.3 | 0.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | -247.06 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.acquisitions-net | -180.66 | 0 | 22.9 | 75 | |||||||
cash-flows.row.purchases-of-investments | -225.84 | -225.8 | -415.4 | -292.5 | |||||||
cash-flows.row.sales-maturities-of-investments | 406.5 | 406.5 | 351.5 | 217.6 | |||||||
cash-flows.row.other-investing-activites | 180.66 | 0 | -22.9 | -75 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 180.23 | 180.2 | -87.2 | -76 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.common-stock-issued | 100.26 | 101.3 | 176 | 207.5 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 12.5 | 0.8 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.other-financing-activites | 101.32 | 5.6 | 358.9 | 218.3 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 101.32 | 101.3 | 301.8 | 281.9 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.05 | -0.1 | 0 | 0 | |||||||
cash-flows.row.net-change-in-cash | 34.45 | 34.4 | -43.1 | 31.4 | |||||||
cash-flows.row.cash-at-end-of-period | 386.09 | 89.3 | 54.9 | 98 | |||||||
cash-flows.row.cash-at-beginning-of-period | 351.64 | 54.9 | 98 | 66.6 | |||||||
cash-flows.row.operating-cash-flow | -247.06 | -247.1 | -257.7 | -174.6 | |||||||
cash-flows.row.capital-expenditure | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.free-cash-flow | -247.49 | -247.5 | -281 | -175.6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 59.61 | 59.6 | 3.7 | 0 | |||||||
income-statement-row.row.cost-of-revenue | 5.18 | 6.1 | 0.8 | 0.8 | |||||||
income-statement-row.row.gross-profit | 54.42 | 53.5 | 2.9 | -0.8 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 110.58 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 235.81 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.other-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.operating-expenses | 295.52 | 294.6 | 304.6 | 206.5 | |||||||
income-statement-row.row.cost-and-expenses | 300.71 | 300.7 | 305.3 | 206.5 | |||||||
income-statement-row.row.interest-income | 12.9 | 0 | 9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.total-operating-expenses | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 6.7 | 1.9 | 5.8 | 0.5 | |||||||
income-statement-row.row.ebitda-caps | -231.67 | - | - | - | |||||||
income-statement-row.row.operating-income | -241.1 | -241.1 | -301.6 | -206.5 | |||||||
income-statement-row.row.income-before-tax | -259.09 | -259 | -311.5 | -206.4 | |||||||
income-statement-row.row.income-tax-expense | 12.77 | 3.1 | 9.8 | -0.5 | |||||||
income-statement-row.row.net-income | -261.78 | -262.1 | -321.3 | -205.9 |
Vaak gestelde vragen
Wat is Arcutis Biotherapeutics, Inc. (ARQT) totale activa?
Arcutis Biotherapeutics, Inc. (ARQT) totale activa is 341365000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 51635000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.913.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -4.392.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -4.045.
Wat is Arcutis Biotherapeutics, Inc. (ARQT) nettowinst (netto-inkomen)?
De nettowinst is -262140000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 205916000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 294589000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 89323000.000.